Best CDMOs in United Kingdom — Ranked by Signal Score · 2026

· updated as new inspection, certificate, and trial data enters the platform
USA Europe Asia UK India Switzerland Germany South Korea Japan China
18
CDMOs in region
18
Fully scored
7
With FDA records
24
FDA inspections
69
EMA/MHRA GMP certs

CDMO Signal tracks 18 biopharma CDMOs with confirmed United Kingdom manufacturing facilities, of which 18 are fully scored across the four-pillar composite Signal Score. Across all modalities, Charles River Laboratories, ReciBioPharm, and Pharmaron Biologics lead the United Kingdom ranking by composite score. Signal Score integrates FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor footprint, and monitored capacity signals. For modality-specific rankings within United Kingdom — AAV, cell therapy, biologics, and 10 other tracked modalities — see the modality-region breakdown below. Full methodology at cdmosignal.com/methodology.

UK-based CDMOs ranked by CDMO Signal's composite Signal Score, filtered to manufacturers with confirmed British facilities. Post-Brexit UK operates under MHRA as an independent regulator distinct from EMA, though the two frameworks broadly align on GMP standards. UK CDMOs supplying EU markets require both MHRA and EMA GMP certification; those supplying US markets need FDA inspection posture. This ranking includes any CDMO with a UK manufacturing site — a CDMO with UK + EU + US facilities appears on each region ranking. Filtering is derived from each CDMO's declared facility locations.

# CDMO Signal Score Quality FDA · GMP Capacity Programs
1
CR
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
 90.9 98.3 8 insp · 11 GMP Limited 0 programs
2
RP
ReciBioPharm
Keele, UK · Sodertalje, SE
 88.0 100.0 0 insp · 3 GMP — 0 programs
3
PB
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
 86.9 100.0 3 insp · 0 GMP Available 0 programs
4
TF
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
 81.0 100.0 6 insp · 10 GMP Available 2 programs
5
RC
RoslinCT
Edinburgh, UK · Hopkinton, MA
 80.3 99.0 1 insp · 1 GMP Available 0 programs
6
BR
BioReliance (Merck)
Glasgow, UK · Rockville, MD
 80.2 97.1 4 insp · 8 GMP — 0 programs
7
AA
Ascend Advanced Therapies
London, United Kingdom
 78.1 100.0 0 insp · 1 GMP — 0 programs
8
OR
Ori Biotech
London, United Kingdom
 78.1 100.0 0 insp · 1 GMP — 0 programs
9
XP
eXmoor Pharma
Bristol, United Kingdom
 78.1 100.0 0 insp · 1 GMP — 0 programs
10
AD
Advent Bioservices
London, United Kingdom
 78.1 100.0 0 insp · 2 GMP — 0 programs
11
CK
Codiak BioSciences (Sarepta)
Cambridge, MA
 78.0 100.0 1 insp · 0 GMP — 16 programs
12
SY
Symbiosis Pharmaceutical Services
Stirling, United Kingdom
 76.8 100.0 1 insp · 9 GMP — 0 programs
13
HH
HiTech Health
London, United Kingdom
 76.8 100.0 0 insp · 9 GMP — 0 programs
14
OX
Oxford Biomedica
Oxford, United Kingdom
 76.2 100.0 0 insp · 13 GMP Available 7 programs
15
VB
VintaBio
Cambridge, MA
 59.0 — — — 0 programs
16
CP
Cell and Gene Therapy Catapult
Stevenage, United Kingdom
 59.0 — — — 0 programs
17
VM
Vector BioMed
Cambridge, MA
 59.0 — — — 0 programs
18
EV
Evox Therapeutics
Oxford, United Kingdom
 56.5 — — — 0 programs
How we score CDMOs →

How has post-Brexit MHRA / EMA divergence affected UK CDMO selection?

Since 1 January 2021 the UK has operated MHRA as an independent regulator distinct from EMA. Practically this means: (1) UK manufacturing for EU-market supply requires a separate EMA GMP certificate, held by an EU-based Qualified Person; (2) EU manufacturing for UK-market supply requires MHRA acceptance, though MHRA has continued to recognize EMA GMP inspections under transitional arrangements; (3) the batches themselves may need to be released twice (once by an EU QP for EU supply, once by a UK QP for UK supply). CDMOs with UK + EU footprints are increasingly common in response; UK-only CDMOs need to arrange separate EU QP release for European supply. The Signal Score's Quality Compliance pillar captures both MHRA and EMA GMP certificates, so dual-jurisdiction CDMOs typically rank higher on this pillar.

Which UK CDMOs also cover FDA (US) regulatory geography?

UK CDMOs with US FDA inspection history qualify to supply US-market programs; those without FDA posture are limited to UK + EU. British CDMOs with FDA inspection density typically rank higher on the Signal Score's Quality Compliance pillar because that pillar aggregates FDA + EMA + MHRA data directly. Cross-check with the US region ranking — CDMOs appearing on both UK and US rankings have demonstrated multi-jurisdictional inspection posture, which materially reduces regulatory tech-transfer risk for programs supplying both markets.

How CDMO Signal identifies UK manufacturing presence

UK region attribution derives from each CDMO's declared facility locations. A location string containing UK-specific tokens (England, Scotland, Wales, Northern Ireland, London, Oxford, Cambridge, Liverpool, Manchester, Edinburgh, or 'UK'/'United Kingdom') places the CDMO in the UK region. Multi-site CDMOs appear in every applicable region — a Cambridge + Basel + Boston CDMO shows on UK, Europe, Switzerland, and USA rankings. Sponsors evaluating for a specific program should verify facility-level detail on the individual CDMO profile page — a CDMO with UK presence may only run some processes there and route others through their non-UK sites.

Browse by modality within United Kingdom

Modality-specific rankings for United Kingdom-manufactured programs. Each page filters the modality's global ranking to CDMOs with confirmed United Kingdom facilities.

AAV / Gene Therapy (12) CAR-T (4) Lentiviral Vector (10) Cell Therapy (7) mRNA / LNP (1) Plasmid DNA (6) Biologics / mAb (1) Adenoviral Vector (2) Gene Editing (2) Exosome / Extracellular Vesicle (2) Recombinant Proteins (1) ADC (Antibody-Drug Conjugate) (1) Gene Therapy (12) Cell & Gene Therapy (16) Viral Vector (12)
Other regions
CDMOs in United States CDMOs in Europe CDMOs in Asia CDMOs in India CDMOs in Switzerland CDMOs in Germany CDMOs in South Korea CDMOs in Japan CDMOs in China